Research
Hormonal
Dietary carbohydrate restriction improves cardiovascular risk markers (Triglycerides, HDL, SFA) more effectively than low-fat diets, regardless of dietary saturated fat intake.
To improve your heart health markers (Triglycerides and HDL), restrict carbohydrates. This lowers triglycerides and raises HDL more effectively than low-fat diets. You do not need to avoid saturated fats; in fact, restricting carbs lowers the saturated fatty acids in your blood, which are the actual risk factor.
GoodSupportsHIGH confidence
Carbohydrate restriction is the single most effective intervention for reducing all of the features of metabolic syndrome... The low-carbohydrate diet (reddish bar) shows the greatest decrease in TG, as well as decrease in weight, HbA1c and glucose and a greater increase in HDL.
Why this rating
Cites studies showing improved lipid profiles on low-carb diets.
Source
Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base
Richard D. Feinman et al. · Nutrition · 2014
DOI 10.1016/j.nut.2014.06.011
narrative_reviewCited 919×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary carbohydrate restriction is the most effective first-line intervention for reducing blood glucose and HbA1c in type 2 diabetes, often allowing for medication reduction or elimination without requiring weight loss.Good
- Dietary carbohydrate restriction is superior to low-fat diets for weight loss in individuals with Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →